Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy

被引:125
|
作者
Rapoport, Bernardo L. [1 ,2 ]
Anderson, Ronald [1 ,3 ]
机构
[1] Univ Pretoria, Dept Immunol, Fac Hlth Sci, ZA-0001 Pretoria, South Africa
[2] Med Oncol Ctr Rosebank, ZA-2196 Johannesburg, South Africa
[3] Univ Pretoria, Inst Cellular & Mol Med, Fac Hlth Sci, ZA-0001 Pretoria, South Africa
来源
关键词
calreticulin; damage-associated molecular patterns (DAMPs); dendritic cells; high mobility group box1; immunogenic cell death; immune checkpoint inhibitors; monoclonal antibodies; type I interferons; ANTITUMOR IMMUNITY; DNA-DAMAGE; T-CELLS; CALRETICULIN EXPOSURE; CROSS-PRESENTATION; DENDRITIC CELLS; LIGAND; TUMOR; INFLAMMATION; MECHANISMS;
D O I
10.3390/ijms20040959
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunogenic cell death (ICD), which is triggered by exposure of tumor cells to a limited range of anticancer drugs, radiotherapy, and photodynamic therapy, represents a recent innovation in the revitalized and burgeoning field of oncoimmunnotherapy. ICD results in the cellular redistribution and extracellular release of damage-associated molecular patterns (DAMPs), which have the potential to activate and restore tumor-targeted immune responses. Although a convincing body of evidence exists with respect to the antitumor efficacy of ICD in various experimental systems, especially murine models of experimental anticancer immunotherapy, evidence for the existence of ICD in the clinical setting is less compelling. Following overviews of hallmark developments, which have sparked the revival of interest in the field of oncoimmunotherapy, types of tumor cell death and the various DAMPs most prominently involved in the activation of antitumor immune responses, the remainder of this review is focused on strategies which may potentiate ICD in the clinical setting. These include identification of tumor- and host-related factors predictive of the efficacy of ICD, the clinical utility of combinatorial immunotherapeutic strategies, novel small molecule inducers of ICD, novel and repurposed small molecule immunostimulants, as well as the critical requirement for validated biomarkers in predicting the efficacy of ICD.
引用
收藏
页数:27
相关论文
共 50 条
  • [41] Targeting immunogenic cell death for cancer immunotherapy
    Qingfei Zhang
    Lu Fan
    Gaizhen Kuang
    Yuanjin Zhao
    Medicine Plus, 2024, 1 (01) : 18 - 22
  • [42] Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer
    Oresta, Bianca
    Pozzi, Chiara
    Braga, Daniele
    Hurle, Rodolfo
    Lazzeri, Massimo
    Colombo, Piergiuseppe
    Frego, Nicola
    Erreni, Marco
    Faccani, Cristina
    Elefante, Grazia
    Barcella, Matteo
    Guazzoni, Giorgio
    Rescigno, Maria
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (575)
  • [43] Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy
    Janicka, Martyna
    Gubernator, Jerzy
    EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (09) : 1059 - 1075
  • [44] Immunogenic cell death-inducing small molecule inhibitors: Potential for immunotherapy of cancer
    Guo, Zong Sheng
    Kalinski, Pawel
    Chen, Hongqi
    Zhu, Zhi
    CLINICAL AND TRANSLATIONAL DISCOVERY, 2022, 2 (02):
  • [45] CLINICAL CANCER CHEMOTHERAPY AIMED AT POTENTIAL CELL REGULATORS
    KNOCK, FE
    GALT, RM
    RENAUD, OV
    OESTER, YT
    ARCHIVES OF SURGERY, 1970, 100 (02) : 167 - &
  • [46] Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment
    Zhu, Songxin
    Wang, Yuming
    Tang, Jun
    Cao, Min
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [47] Radiotherapy in combination with hyperthermia induces immunogenic tumor cell death forms - implications for multimodal cancer therapies
    Schildkopf, P.
    Ott, O. J.
    Sieber, R.
    Janko, C.
    Mantel, F.
    Weiss, E. -M.
    Frey, B.
    Fietkau, R.
    Gaipl, U. S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 162 - 162
  • [48] Trial watch: chemotherapy-induced immunogenic cell death in oncology
    Sprooten, Jenny
    Laureano, Raquel S.
    Vanmeerbeek, Isaure
    Govaerts, Jannes
    Naulaerts, Stefan
    Borras, Daniel M.
    Kinget, Lisa
    Fucikova, Jitka
    Spisek, Radek
    Jelinkova, Lenka Palova
    Kepp, Oliver
    Kroemer, Guido
    Krysko, Dmitri V.
    Coosemans, An
    Vaes, Rianne D. W.
    De Ruysscher, Dirk
    De Vleeschouwer, Steven
    Wauters, Els
    Smits, Evelien
    Tejpar, Sabine
    Beuselinck, Benoit
    Hatse, Sigrid
    Wildiers, Hans
    Clement, Paul M.
    Vandenabeele, Peter
    Zitvogel, Laurence
    Garg, Abhishek D.
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [49] Critical role of immunogenic cell death in cancer therapy
    Xia, Tian
    SCIENCE BULLETIN, 2017, 62 (21) : 1427 - 1429
  • [50] TFAM is a novel mediator of immunogenic cancer cell death
    Yang, Minghua
    Li, Changfeng
    Zhu, Shan
    Cao, Lizhi
    Kroemer, Guido
    Zeh, Herbert
    Tang, Daolin
    Kang, Rui
    ONCOIMMUNOLOGY, 2018, 7 (06):